| Literature DB >> 25768700 |
Sergio Valente1, Veronica Rodriguez1, Ciro Mercurio2, Paola Vianello3, Bruna Saponara4, Roberto Cirilli4, Giuseppe Ciossani5, Donatella Labella1, Biagina Marrocco1, Daria Monaldi1, Giovanni Ruoppolo6, Mats Tilset7, Oronza A Botrugno3, Paola Dessanti3, Saverio Minucci8, Andrea Mattevi5, Mario Varasi3, Antonello Mai9.
Abstract
The pure enantiomers of the N-(2-, 3-, and 4-(2-aminocyclopropyl)phenyl)benzamides hydrochlorides 11a-j were prepared and tested against LSD1 and MAO enzymes. The evaluation of the regioisomers 11a-j highlighted a net increase of the anti-LSD1 potency by shifting the benzamide moiety from ortho to meta and mainly to para position of tranylcypromine phenyl ring, independently from their trans or cis stereochemistry. In particular, the para-substituted 11a,b (trans) and 11g,h (cis) compounds displayed LSD1 and MAO-A inhibition at low nanomolar levels, while were less potent against MAO-B. The meta analogs 11c,d (trans) and 11i,j (cis) were in general less potent, but more efficient against MAO-A than against LSD1. In cellular assays, all the para and meta enantiomers were able to inhibit LSD1 by inducing Gfi-1b and ITGAM gene expression, with 11b,c and 11g-i giving the highest effects. Moreover, 11b and 11g,h strongly inhibited the clonogenic potential of murine promyelocytic blasts.Entities:
Keywords: Epigenetics; Leukemia; Lysine-specific demethylase 1; Stereoisomers; Tranylcypromine
Mesh:
Substances:
Year: 2015 PMID: 25768700 DOI: 10.1016/j.ejmech.2015.02.060
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514